for Migraine Prevention
... to live a migraine-free life
Migraine Questions?
1-866-367-5953
• Why This Works
• Reviews
• FAQ about MD
• Guarantee
• Ingredients
• Migraine Library
• Migraine Research
• Migraine Stages
• Migraine Triggers
• Migraine Types
• Primary Case
• Print Migraine Diary
• Products List
ORDER
Migraine Defense
CHECK OUT
 
Tuliv Migraine Defense is stores

References

This is by no means a complete or all inclusive list of the many references used by the Tuliv Migraine Research project, but it does include some of those found to be helpful in our study of migraines.

  1. Noboru Toda and Tomio Okamura, The Pharmacology of Nitric Oxide in the Peripheral Nervous System of Blood Vessels, Affiliations Department of Pharmacology, Shiga University of Medical Science, Ohtsu, Japan (N.T., T.O.); and Department of Toyama Institute for Cardiovascular Pharmacology Research, Chuo-ku, Osaka, Japan Pharmacol Rev 55:271–324, 2003
  2. Zacharias L, Rand WM, Wurtman RJ. A prospective study of sexual development and growth in American girls: The statistics of menarchie. Obstet Gynecol Surv. 1976;31(4):325-337.
  3. Harlan WR, Harlan EA, Grillo GP. Secondary sex characteristics of girls 12 to 17 years of age: The U.S. Health Examination Survey. J Pediatr. 1980;96(6):1074-1078.
  4. Jenner MR, Kelch RP, Kaplan SL, Grumbach MM. Hormonal changes in puberty. IV. Plasma estradiol, LH, and FSH in prepubertal children, pubertal females, and in precocious puberty, premature thelarche, hypogonadism, and in a child with a feminizing ovarian tumor. J Clin Endocrinol Metab. 1972;34(3):521-530.
  5. Stewart WF, Lipton RB, Celentano DD, Reed ML. Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors. JAMA. 1992;267(1):64-69.
  6. Stewart WF, Linet MS, Celentano DD, Van Natta M, Ziegler D. Age- and sex-specific incidence rates of migraine with and without visual aura. Am J Epidemiol. 1991;134(10):1111-1120.
  7. Couturier EG, Bomhof MA, Neven AK, van Duijn NP. Menstrual migraine in a representative Dutch population sample: Prevalence, disability and treatment. Cephalalgia. 2003;23(4):302-308.
  8. Martin VT. Menstrual migraine: A review of prophylactic therapies. Curr Pain Headache Rep. 2004;8(3):229-237.
  9. MacGregor EA, Chia H, Vohrah RC, Wilkinson M. Migraine and menstruation: A pilot study. Cephalalgia. 1990;10(6):305-310.
  10. Granella F, Sances G, Zanferrari C, Costa A, Martignoni E, Manzoni GC. Migraine without aura and reproductive life events: A clinical epidemiological study in 1300 women. Headache. 1993;33(7):385-389.
  11. Granella F, Sances G, Pucci E, Nappi RE, Ghiotto N, Napp G. Migraine with aura and reproductive life events: A case control study. Cephalalgia. 2000;20(8):701-707.
  12. Cupini LM, Matteis M, Troisi E, Calabresi P, Bernardi G, Silvestrini M. Sex-hormone-related events in migrainous females. A clinical comparative study between migraine with aura and migraine without aura. Cephalalgia. 1995;15(2):140-144.
  13. Mattsson P. Hormonal factors in migraine: A population-based study of women aged 40 to 74 years. Headache. 2003;43(1):27-35.
  14. Koseoglu E, Nacar M, Talaslioglu A, Cetinkaya F. Epidemiological and clinical characteristics of migraine and tension type headache in 1146 females in Kayseri, Turkey. Cephalalgia. 2003;23(5):381-388.
  15. Johannes CB, Linet MS, Stewart WF, Celentano DD, Lipton RB, Szklo M. Relationship of headache to phase of the menstrual cycle among young women: A daily diary study. Neurology. 1995;45(6):1076-1082.
  16. Stewart WF, Lipton RB, Chee E, Sawyer J, Silberstein SD. Menstrual cycle and headache in a population sample of migraineurs. Neurology. 2000;55(10):1517-1523.
  17. Martin V, Wernke S, Mandell K, Grumbach MM. Defining the relationship between ovarian hormones and migraine headache. Headache. 2005;45: 1190-1201.
  18. MacGregor EA, Hackshaw A. Prevalence of migraine on each day of the natural menstrual cycle. Neurology. 2004;63(2):351-353.
  19. Granella F, Sances G, Allais G, Nappi RE, Tirelli A, Benedetto C, et al. Characteristics of menstrual and nonmenstrual attacks in women with menstrually related migraine referred to headache centres. Cephalalgia. 2004;24(9):707-716.
  20. Davies PT, Eccles N, Steiner TJ, Leathard H, Rose F. Plasma estrogen, progesterone and sex hormone binding globulin levels in the pathogenesis of migraine. Cephalalgia. 1989;9: 143[abstract].
  21. Epstein MT, Hockaday JM, Hockaday TD. Migraine and reproductive hormones throughout the menstrual cycle. Lancet. 1975;1(7906):543-548.
  22. Lichten EM, Lichten J, Whitty A, Peiper D. The use of leuprolide acetate in the diagnosis and treatment of menstrual migraine: The role of artificially induced menopause. Headache Q. 1995;6: 313-317.
  23. Murray SC, Muse KN. Effective treatment of severe menstrual migraine headaches with gonadotropin-releasing hormone agonist and "add-back" therapy. Fertil Steril. 1997;67(2):390-393.
  24. Somerville BW. Plasma estradiol level linked to migraine during menstrual period. JAMA. 1972;221: 845-846.
  25. Somerville BW. The role of estradiol withdrawal in the etiology of menstrual migraine. Neurology. 1972;22(4):355-365.
  26. Somerville BW. Estrogen-withdrawal migraine. II. Attempted prophylaxis by continuous estradiol administration. Neurology. 1975;25(3):245-250.
  27. Somerville BW. Estrogen-withdrawal migraine. I. Duration of exposure required and attempted prophylaxis by premenstrual estrogen administration. Neurology. 1975;25(3):239-244.
  28. de Lignieres B, Vincens M, Mauvais-Jarvis P, Mas JL, Touboul PJ, Bousser MG. Prevention of menstrual migraine by percutaneous oestradiol. Br Med J (Clin Res Ed). 1986;293(6561):1540.
  29. Calhoun AH. A novel specific prophylaxis for menstrual-associated migraine. South Med J. 2004;97(9):819-822.
  30. Pradalier A, Vincent D, Beaulieu P, Baudesson G, Launay J. Correlation between oestradiol plasma level and therapeutic effect on menstrual migraine. In: Rose C, ed. New Advances in Headache Research: 4. London: Smith-Gordon, 1994, pp. 129-132.
  31. Silberstein SD, Merriam GR. Estrogens, progestins, and headache. Neurology. 1991;41(6):786-793.
  32. Carlson LA, Ekelund LG, Oro L. Clinical and metabolic effects of different doses of prostaglandin E1 in man. Prostaglandin and related factors. Acta Med Scand. 1968;183(5):423-430.
  33. Irwin J, Morse E, Riddick D. Dysmenorrhea induced by autologous transfusion. Obstet Gynecol. 1981;58(3):286-290.
  34. Sances G, Martignoni E, Fioroni L, Blandini F, Facchinetti F, Nappi G. Naproxen sodium in menstrual migraine prophylaxis: A double-blind placebo controlled study. Headache. 1990;30(11):705-709.
  35. Li W, Zheng T, Altura BM, Altura BT. Sex steroid hormones exert biphasic effects on cytosolic magnesium ions in cerebral vascular smooth muscle cells: Possible relationships to migraine frequency in premenstrual syndromes and stroke incidence. Brain Res Bull. 2001;54(1):83-89.
  36. Ramadan NM, Halvorson H, Vande-Linde A, Levine SR, Helpern JA, Welch KM. Low brain magnesium in migraine. Headache. 1989;29(7):416-419.
  37. Mauskop A, Altura BM. Role of magnesium in the pathogenesis and treatment of migraines. Clin Neurosci. 1998;5(1):24-27.
  38. Mauskop A, Altura BT, Cracco RQ, Altura BM. Intravenous magnesium sulphate relieves migraine attacks in patients with low serum ionized magnesium levels: A pilot study. Clin Sci (Lond). 1995;89(6):633-636.
  39. Facchinetti F, Sances G, Borella P, Genazzani AR, Nappi G. Magnesium prophylaxis of menstrual migraine: Effects on intracellular magnesium. Headache. 1991;31(5):298-301.
  40. Facchinetti F, Martignoni E, Fioroni L, Sances G, Genazzani AR. Opioid control of the hypothalamus-pituitary-adrenal axis cyclically fails in menstrual migraine. Cephalalgia. 1990;10(1):51-56.
  41. Cassidy EM, Tomkins E, Dinan T, Hardiman O, O'Keane V. Central 5-HT receptor hypersensitivity in migraine without aura. Cephalalgia. 2003;23(1):29-34.
  42. Nappi RE, Sances G, Brundu B, Ghiotto N, Detaddei S, Biancardi C, et al. Neuroendocrine response to the serotonin agonist M-chlorophenylpiperazine in women with menstrual status migrainosus. Neuroendocrinology. 2003;78(1):52-60.
  43. Cassidy EM, Tomkins E, Sharifi N, Dinan T, Hardiman O, O'Keane V. Differing central amine receptor sensitivity in different migraine subtypes? A neuroendocrine study using buspirone. Pain. 2003;101(3):283-290.
  44. D'Andrea G, Hasselmark L, Cananzi AR, Alecci M, Perini F, Zamberlan F, et al. Metabolism and menstrual cycle rhythmicity of serotonin in primary headaches. Headache. 1995;35(4):216-221.
  45. Fioroni L, Andrea GD, Alecci M, Cananzi A, Facchinetti F. Platelet serotonin pathway in menstrual migraine. Cephalalgia. 1996;16(6):427-430.
  46. Sarchielli P, Tognoloni M, Russo S, Vulcano MR, Feleppa M, Mala M, et al. Variations in the platelet arginine/nitric oxide pathway during the ovarian cycle in females affected by menstrual migraine. Cephalalgia. 1996;16(7):468-475.
  47. Smith CC, McMahon LL. Estrogen-induced increase in the magnitude of long-term potentiation occurs only when the ratio of NMDA transmission to AMPA transmission is increased. J Neurosci. 2005;25(34):7780-7791.
  48. Woolley CS. Estrogen-mediated structural and functional synaptic plasticity in the female rat hippocampus. Horm Behav. 1998;34(2):140-148.
  49. Martin V, Behbehani M. Ovarian hormones and migraine headache: Understanding mechanisms and pathogenesis—Part 1. Headache. 2006.
  50. Stell BM, Brickley SG, Tang CY, Farrant M, Mody I. Neuroactive steroids reduce neuronal excitability by selectively enhancing tonic inhibition mediated by delta subunit-containing GABAA receptors. Proc Natl Acad Sci U S A. 2003;100(24):14439-14444.
  51. Beckham JC, Krug LM, Penzien DB, Johnson CA, Mosley TH, Meeks GR, et al. The relationship of ovarian steroids, headache activity and menstrual distress: A pilot study with female migraineurs. Headache. 1992;32(6):292-297.
  52. Cutrer FM, Moskowitz MA. Wolff Award 1996. The actions of valproate and neurosteroids in a model of trigeminal pain. Headache. 1996;36(10):579-585.
  53. Limmroth V, Lee WS, Moskowitz MA. GABAA-receptor-mediated effects of progesterone, its ring-A-reduced metabolites and synthetic neuroactive steroids on neurogenic oedema in the rat meninges. Br J Pharmacol. 1996;117(1):99-104.
  54. Allais G, De Lorenzo C, Mana O, Benedetto C. Oral contraceptives in women with migraine: Balancing risks and benefits. Neurol Sci. 2004;25 (suppl 3):S211-S214.
  55. Ryan RE. A controlled study of the effect of oral contraceptives on migraine. Headache. 1978;17(6):250-251.
  56. Whitty CW, Hockaday JM, Whitty MM. The effect of oral contraceptives on migraine. Lancet. 1966;1(7442):856-859.
  57. Dalton K. Migraine and oral contraceptives. Headache. 1976;15: 247-251.
  58. Mueller L. Predictability of exogenous hormone effect on subgroups of migraineurs. Headache. 2000;40(3):189-193.
  59. Loder EW, Buse DC, Golub JR. Headache and combination estrogen-progestin oral contraceptives: Integrating evidence, guidelines, and clinical practice. Headache. 2005;45(3):224-231.
  60. Cachrimanidou AC, Hellberg D, Nilsson S, Waldenstrom U, Olsson SE, Sikstrom B. Long-interval treatment regimen with a desogestrel-containing oral contraceptive. Contraception. 1993;48(3):205-216.
  61. Mousa GY. Migraine and oral contraceptives. Am J Optom Physiol Opt. 1982;59(10):821-823.
  62. Horenstein S. Neurological disorders associated with oral contraceptives. Trans N Engl Obstet Gynecol Soc. 1967;21: 159-172.
  63. Gardner JH, Horenstein S, Van den Noort S. The clinical characteristics of headache during impending cerebral infarction in women taking oral contraceptives. Headache. 1968;8(3):108-111.
  64. Hanington E, Jones R, Amess J. Platelet aggregation in response to 5HT in migraine patients taking oral contraceptives. Lancet. 1982;1: 967-968.
  65. Stang PE, Carson AP, Rose KM, Mo J, Ephross SA, Shahar E, et al. Headache, cerebrovascular symptoms, and stroke: The Atherosclerosis Risk in Communities Study. Neurology. 2005;64(9):1573-1577.
  66. Tzourio C, Bousser MG. Migraine: A risk factor for ischemic stroke in young women. Stroke. 1997;28(12):2569-2570.
  67. Tzourio C, Iglesias S, Hubert JB, Visy JM, Alperovitch A, Tehindrazanarivelo A, et al. Migraine and risk of ischaemic stroke: A case–control study. BMJ. 1993;307(6899):289-292.
  68. Chang CL, Donaghy M, Poulter N. Migraine and stroke in young women: Case–control study. The World Health Organisation Collaborative Study of cardiovascular disease and steroid hormone contraception. BMJ. 1999;318(7175):13-18.
  69. Velentgas P, Cole JA, Mo J, Sikes CR, Walker AM. Severe vascular events in migraine patients. Headache. 2004;44(7):642-651.
  70. Etminan M, Takkouche B, Isorna FC, Samii A. Risk of ischaemic stroke in people with migraine: Systematic review and meta-analysis of observational studies. BMJ. 2005;330(7482):63.
  71. Lidegaard O, Kreiner S. Contraceptives and cerebral thrombosis: A five-year national case–control study. Contraception. 2002;65(3):197-205.
  72. Lidegaard O, Edstrom B, Kreiner S. Oral contraceptives and venous thromboembolism. A case–control study. Contraception. 1998;57(5):291-301.
  73. Slooter AJ, Rosendaal FR, Tanis BC, Kemmeren JM, van der Graaf Y, Algra A. Prothrombotic conditions, oral contraceptives, and the risk of ischemic stroke. J Thromb Haemost. 2005;3(6):1213-1217.
  74. Tzourio C, Tehindrazanarivelo A, Iglesias S, Alperovitch A, Chedru F, d'Anglejan-Chatillon J, et al. Case–control study of migraine and risk of ischaemic stroke in young women. BMJ. 1995;310(6983):830-833.
  75. Improving Access to Quality Care in Family Planning: Medical Eligibility Criteria for Contraceptive Use, 2nd ed. Geneva: World Health Organization, 2000.
  76. Bousser MG, Conard J, Kittner S, de Lignieres B, MacGregor EA, Massiou H, et al. Recommendations on the risk of ischaemic stroke associated with use of combined oral contraceptives and hormone replacement therapy in women with migraine. The International Headache Society Task Force on combined oral contraceptives & hormone replacement therapy. Cephalalgia. 2000;20(3):155-156.
  77. The use of hormonal contraceptives in patients with coexisting medical conditions: ACOG practice bulletin no. 18. Int J Gynecol Obstet. 2001;75: 93-106.
  78. Tulchinsky D, Hobel CJ, Yeager E, Marshall JR. Plasma estrone, estradiol, estriol, progesterone, and 17-hydroxyprogesterone in human pregnancy. I. Normal pregnancy. Am J Obstet Gynecol. 1972;112(8):1095-1100.
  79. Speroff L, Glass R, Kase N. Clinical Endocrinology and Infertility, 5th ed. Baltimore: Williams & Wilkins, 1994.
  80. Sances G, Granella F, Nappi RE, Fignon A, Ghiotto N, Polatti F, et al. Course of migraine during pregnancy and postpartum: A prospective study. Cephalalgia. 2003;23(3):197-205.
  81. Chen TC, Leviton A. Headache recurrence in pregnant women with migraine. Headache. 1994;34(2):107-110.
  82. Somerville BW. A study of migraine in pregnancy. Neurology. 1972;22(8):824-828.
  83. Rasmussen BK. Migraine and tension-type headache in a general population: Precipitating factors, female hormones, sleep pattern and relation to lifestyle. Pain. 1993;53(1):65-72.
  84. Ratinahirana Y, Darbois Y, Bousser MG. Migraine and pregnancy: A prospective study in 703 women. Neurology. 1990;40(suppl 1):437.
  85. Ertresvag J, Zwart J, Helde G, Johnsen H, Bovim G. Headache and transient focal neurological symptoms during pregnancy, a prospective cohort. Acta Neurol Scand. 2005;111: 233-237.
  86. Chancellor AM, Wroe SJ, Cull RE. Migraine occurring for the first time in pregnancy. Headache. 1990;30(4):224-227.
  87. Wright GD, Patel MK. Focal migraine and pregnancy. Br Med J (Clin Res Ed). 1986;293(6561):1557-1558.
  88. Kelman L. Women's issues of migraine in tertiary care. Headache. 2004;44(1):2-7.
  89. Medina VM, Dawson-Basoa ME, Gintzler AR. 17 beta-estradiol and progesterone positively modulate spinal cord dynorphin: Relevance to the analgesia of pregnancy. Neuroendocrinology. 1993;58(3):310-315.
  90. Campbell OM, Gray RH. Characteristics and determinants of postpartum ovarian function in women in the United States. Am J Obstet Gynecol. 1993;169(1):55-60.
  91. Labbok MH, Hight-Laukaran V, Peterson AE, Fletcher V, von Hertzen H, Van Look PF. Multicenter study of the Lactational Amenorrhea Method (LAM): I. Efficacy, duration, and implications for clinical application. Contraception. 1997;55(6):327-336.
  92. Marcus DA, Scharff L, Turk D. Longitudinal prospective study of headache during pregnancy and postpartum. Headache. 1999;39(9):625-632.
  93. World Health Organization Scientific Group. Report of WHO Scientific Group: Research on the Menopause in the 1990's. Geneva, Switzerland: World Health Organization; 1996.
  94. Greendale GA, Lee NP, Arriola ER. The menopause. Lancet. 1999;353(9152):571-580.
  95. Santoro N, Brown JR, Adel T, Skurnick JH. Characterization of reproductive hormonal dynamics in the perimenopause. J Clin Endocrinol Metab. 1996;81(4):1495-1501.
  96. Wang SJ, Fuh JL, Lu SR, Juang KD, Wang PH. Migraine prevalence during menopausal transition. Headache. 2003;43(5):470-478.
  97. Fettes I. Migraine in the menopause. Neurology. 1999;53(4 suppl 1):S29-S33.
  98. Greendale GA, Reboussin BA, Hogan P, Barnabei VM, Shumaker S, Johnson S, et al. Symptom relief and side effects of postmenopausal hormones: Results from the Postmenopausal Estrogen/Progestin Interventions Trial. Obstet Gynecol. 1998;92(6):982-988.
  99. Nelson AL. Extended-cycle oral contraception: A new option for routine use. Treat Endocrinol. 2005;4(3):139-145.
  100. Whitty C, Hockaday JM. Migraine: A follow-up of 92 patients. BMJ. 1968;1: 735-736.
  101. Hodson J, Thompson J, al-Azzawi F. Headache at menopause and in hormone replacement therapy users. Climacteric. 2000;3(2):119-124.
  102. Neri I, Granella F, Nappi R, Manzoni GC, Facchinetti F, Genazzani AR. Characteristics of headache at menopause: A clinico-epidemiologic study. Maturitas. 1993;17(1):31-37.
  103. Genazzani AR, Petraglia F, Volpe A, Facchinetti F. Estrogen changes as a critical factor in modulation of central opioid tonus: Possible correlations with post-menopausal migraine. Cephalalgia. 1985;5(suppl 2):212-214.
  104. Gonzales GF, Carrillo C. Blood serotonin levels in postmenopausal women: Effects of age and serum oestradiol levels. Maturitas. 1993;17(1):23-29.
  105. Blum I, Vered Y, Lifshitz A, Harel D, Blum M, Nordenberg Y, et al. The effect of estrogen replacement therapy on plasma serotonin and catecholamines of postmenopausal women. Isr J Med Sci. 1996;32(12):1158-1162.
  106. Berendsen HH. The role of serotonin in hot flushes. Maturitas. 2000;36(3):155-164.
  107. Misakian AL, Langer RD, Bensenor IM, Cook NR, Manson JE, Buring JE, et al. Postmenopausal hormone therapy and migraine headache. J Womens Health (Larchmt). 2003;12(10):1027-1036.
  108. Kaiser HJ, Meienberg O. Deterioration or onset of migraine under oestrogen replacement therapy in the menopause. J Neurol. 1993;240(3):195-196.
  109. MacGregor A. Estrogen replacement and migraine aura. Headache. 1999;39(9):674-678.
  110. Martin V, Wernke S, Mandell K, Zoma W, Bean J, Pinney S, et al. Medical oophorectomy with and without estrogen add-back therapy in the prevention of migraine headache. Headache. 2003;43(4):309-321.
  111. Martin V, Liu J, Wernke S, Mandell K, Bean J, Rebar R. The dose of transdermal estradiol and its role in migraine headache. Headache. 2003;43: 547-548[abstract].
  112. Nappi RE, Cagnacci A, Granella F, Piccinini F, Polatti F, Facchinetti F. Course of primary headaches during hormone replacement therapy. Maturitas. 2001;38(2):157-163.
  113. Stumpf PG. Pharmacokinetics of estrogen. Obstet Gynecol. 1990;75(4 suppl):9S-14S; discussion 15S-17S.
  114. Facchinetti F, Nappi RE, Tirelli A, Polatti F, Nappi G, Sances G. Hormone supplementation differently affects migraine in postmenopausal women. Headache. 2002;42(9):924-929.
  115. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial. JAMA. 2002;288(3):321-333.
  116. Hormone therapy for the prevention of chronic conditions in postmenopausal women: Recommendations from the U.S. Preventive Services Task Force. Ann Intern Med. 2005;142(10):855-860.
  117. Abramson BL. Postmenopausal hormone replacement therapy for primary prevention of cardiovascular and cerebrovascular disease. Recommendation statement from the Canadian Task Force on Preventive Health Care. CMAJ. 2004;170(9):1388-1389.
  118. Wathen CN, Feig DS, Feightner JW, Abramson BL, Cheung AM. Hormone replacement therapy for the primary prevention of chronic diseases: Recommendation statement from the Canadian Task Force on Preventive Health Care. CMAJ. 2004;170(10):1535-1537.
  119. Mosca L, Appel LJ, Benjamin EJ, Berra K, Chandra-Strobos N, Fabunmi RP, et al. Evidence-based guidelines for cardiovascular disease prevention in women. Circulation. 2004;109(5):672-693.
  120. Recommendations for estrogen and progestogen use in peri- and postmenopausal women: October 2004 position statement of the North American Menopause Society. Menopause. 2004;11(6 Pt 1):589-600.
  121. Somerville BW, Carey HM. The use of continuous progestogen contraception in the treatment of migraine. Med J Aust. 1970;1(21):1043-1045.
  122. Singh I, Singh I, Singh D. Progesterone in the treatment of migraine. Lancet. 1947;1: 745-747.
  123. Bradley W, Hudgson P, Foster J, Newell D. Double-blind controlled trial of a micronized preparation of flumedroxone (Demigran) in prophylaxis of migraine. BMJ. 1968;3: 531-533.
  124. Davies P, Fursdon-Davies C, Rees MC. Progestogens for menstrual migraine. J Br Menopause Soc. 2003;9(3):134.
  125. Kaunitz AM. Injectable depot medroxyprogesterone acetate contraception: An update for U.S. clinicians. Int J Fertil Womens Med. 1998;43(2):73-83.
  126. Sivin I. International experience with NORPLANT and NORPLANT-2 contraceptives. Stud Fam Plann. 1988;19(2):81-94.
  127. Greenblatt RB, Bruneteau DW. Menopausal headaches—psychogenic or metabolic? J Am Geriatr Soc. 1974;22(4):186-190.
  128. Lichten EM, Lichten JB, Whitty A, Pieper D. The confirmation of a biochemical marker for women's hormonal migraine: The depo-estradiol challenge test. Headache. 1996;36(6):367-371.
  129. Colson NJ, Lea RA, Quinlan S, MacMillan J, Griffiths LR. The estrogen receptor 1 G594A polymorphism is associated with migraine susceptibility in two independent case/control groups. Neurogenetics. 2004;5(2):129-133.
  130. Colson NJ, Lea RA, Quinlan S, MacMillan J, Griffiths LR. Investigation of hormone receptor genes in migraine. Neurogenetics. 2005;6(1):17-23.
  131. Dzoljic E, Sipetic S, Vlajinac H, Marinkovic J, Brzakovic B, Pokrajac M, et al. Prevalence of menstrually related migraine and nonmigraine primary headache in female students of Belgrade University. Headache. 2002;42(3):185-193.
  132. Maggioni F, Alessi C, Maggino T. Primary headache and pregnancy. Cephalalgia. 1995;15: 54[abstract].


Back to Top of Page

Notice: The information on this web site is provided as general health information and may not be applicable to your particular health condition. Medical diagnoses and treatments may be properly addressed by your professional healthcare provider. Tuliv Ltd. Co. shall not be liable for the contents, products, errors or omissions in the information provided, or advise obtained from this web site, written documents, emails, phone conversation, or orders. Tuliv Migraine Defense and other products sold under the name Tuliv or Christian Body are sold as a dietary supplement under the regulations of the FDA The statements made on this web site, in written correspondence, or verbal conversations have not been evaluated by the FDA.

Copyright ® 2004-2011 Tuliv Ltd. Co. All rights reserved. Tuliv® and Migraine Defense® are registered trademarks of Tuliv Ltd. Co.